Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 November 19, 2024
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update November 13, 2024
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition November 5, 2024
Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases November 4, 2024
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases November 4, 2024
